ESMO Annual Congress

Andrew W. Hahn, MD, highlights safety and tolerability data on lenvatinib/everolimus vs cabozantinib for metastatic ccRCC.

Alice Bernard-Tessier, MD, highlights preliminary results from a phase 1 trial of gedatolisib plus darolutamide in mCRPC.

Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC.

Marc Machaalani, MD, shares data on soluble MAdCAM-1 as a predictive biomarker in metastatic renal cell carcinoma.

Data suggest that KIM-1 is prognostic for clinical outcomes in aRCC.

212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy.

Bertrand Tombal, MD, PhD, shares insights from the real-world REASSURE trial.

The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.

Rahul Aggarwal, MD, highlights final results from the phase 3 PRESTO trial in biochemically relapsed prostate cancer.

Qian Qin, MD, outlines the background and design of the phase 2 EXPLORE-RCC trial.

Petros Grivas, MD, PhD, highlights notable trial readouts across NMIBC, MIBC, and urothelial carcinoma.

Pedro C. Barata, MD, MSc, FACP, outlines ARANOTE findings stratified by age subgroups.

Hear from 5 experts as they recap some of the top data from this year's ESMO Congress.

According to the authors, this combination represents a potential new standard of care for this patient population.

Take a look through the top readouts in urologic oncology from ESMO 2025.

Three cycles of chemotherapy was shown to improve patient-reported outcomes vs six cycles, with no detriment to overall survival.

Louise K. Kostos, MBBS, FRACP, PhD candidate, outlines initial findings from the phase 1/2 AlphaBet trial.

Beckermann explained that adenosine blockade may be better shown in the durability of response, so data collection in the study remains ongoing.

Data indicates that the DFS improvement was largely driven by the treatment effect in the higher risk population.

The mean baseline FACT-G total score for the niraparib group was 79.7 (standard deviation [SD], 14.9) and was 79.3 (SD, 15.2) for the placebo group.

In patients who were ctDNA positive, median DFS was 9.9 months (95% CI: 7.2-12.7) in the atezolizumab group vs 4.8 months (95% CI: 4.1-8.3) in the placebo group.

Scott Tagawa, MD, provides an overview of key findings from the PSMAddition study, evaluating 177Lu-PSMA-617 combined with ADT and ARPI in mHSPC.

Jeremie Calais, MD, PhD, shares key findings from the phase 2 LUNAR trial, assessing the safety and efficacy of adding 177Lu-PSMA therapy before SBRT in omHSPC.

“Overall, the combination of saruparib plus an ARPI was well tolerated," Arun Azad, PhD, MBBS.

Enrique Grande, MD, shares key findings from the DISCUS trial, exploring 3 vs 6 cycles of platinum-based chemotherapy for advanced urothelial carcinoma.

"The primary end point was met, showing a statistically significant rPFS benefit with the combination of capivasertib and abiraterone," said Karim Fizazi, MD, PhD.

Regarding the primary end point, “4 patients showed a partial response, leading to a response rate of 17%," said Srikala S. Sridhar, MD, MSc, FRCPC.

Stephen J. Freedland, MD, reported that with combination enzalutamide/leuprolide, the risk of death was 40.3% lower vs leuprolide alone.